NEWARK, N.J., Aug. 17, 2021 /PRNewswire/ -- Rafael
Holdings, Inc., (NYSE: RFL), a pharmaceutical company focused on
developing novel cancer metabolism therapeutics, today announced
the appointment of three senior biopharmaceutical leaders to its
executive management team: Gus Kodersha, Chief Technical Operations
Officer; Melissa Lozner, Chief
Compliance & Ethics Officer; and Brandi
Robinson, Chief Corporate Affairs Officer.
"We are very fortunate to have attracted three seasoned and
accomplished leaders of Gus, Melissa and Brandi's caliber to lead
critical functions at Rafael as we approach the near term
completion of our Phase 3 registrational clinical trial for our
lead investigational agent, CPI-613®, for the treatment of
metastatic pancreatic cancer, advance our registrational Phase 3
clinical trial in r/r AML, and continue our ongoing and planned
clinical trial programs across multiple indications," said
Ameet Mallik, Chief Executive
Officer of Rafael Holdings, Inc. "Each of these leaders
brings invaluable experience and previous successes which will
enable us to maximize the potential of our portfolio of novel
therapeutics with a goal of building a high growth, fully
integrated cancer metabolism therapeutics leader focused on
improving and extending the lives of patients."
Gus Kodersha is an experienced pharmaceutical manufacturing and
operations leader with extensive cross-functional and technical
experience in building and operating a global pharmaceutical
manufacturing and supply chain organization. Most recently, Gus was
the Vice President Tech Ops and CMC at Ovid Therapeutics, and his
career accomplishments include leading CMC technical development
across different clinical stages at start-ups and established
biotech companies. Gus has built company-wide supply chain and
manufacturing networks for more than 10 life sciences small
molecule and biologic products ranging from late-stage clinical
trials through FDA approval and achieving process validation and
industrial-scale commercial readiness.
"I look forward to working with Ameet and the Rafael team to
build a commercial-ready leading cancer metabolism therapeutics
company with the potential to address a large range of cancer
indications and improve the lives of patients," said Gus Kodersha,
Chief Technical Operations Officer.
Melissa Lozner is a highly
experienced legal and compliance leader with 20 years of diverse
international and US experience in the health care industry and
beyond. She was a litigation attorney in private practice and
an in-house corporate attorney prior to serving as Vice President,
Head of Ethics, Risk & Compliance at Novartis. In this
role, Melissa oversaw all aspects of the Ethics, Risk &
Compliance program for the US Oncology business unit and was a
member of the US Oncology Country Leadership Team and Global
Oncology Ethics, Risk & Compliance Leadership Team.
"It is a true pleasure to have another opportunity to work with
Ameet and join the Rafael leadership team as we advance our novel
metabolic approach to fighting cancer and addressing unmet patient
needs," said Melissa Lozner, Chief
Compliance & Ethics Officer.
Brandi Robinson is an
accomplished communications executive that brings more than 20
years of experience in the pharmaceuticals, medical device and
consumer health industries specializing in strategic
communications, media relations, issues management, patient
education campaigns, corporate reputation, and product and internal
communications.
"It is exciting to be joining the Rafael leadership team in
September at this critical inflection point as we complete our
Phase 3 clinical trial for CPI-613® in metastatic pancreatic cancer
and, if positive, prepare for our first NDA submission and
potential commercial launch, assuming favorable regulatory review,"
said Brandi Robinson, Chief
Corporate Affairs Officer.
About Rafael Holdings, Inc.
Rafael Holdings is focused
on the development of novel cancer therapies. The company is
a significant investor in two clinical stage oncology companies,
Rafael Pharmaceuticals, Inc., and LipoMedix Pharmaceuticals
Ltd. Through its wholly owned Barer Institute subsidiary, the
company is developing a pipeline of compounds focused on the
regulation of cancer metabolism. For more information, visit
www.rafaelholdings.com.
About Rafael Pharmaceuticals, Inc.
Rafael
Pharmaceuticals is a clinical-stage oncology company focused on
selectively targeting cancer metabolic pathways while
simultaneously harnessing the immune system to attack hard-to-treat
cancers. The Company's lead drug, CPI-613 (devimistat), is being
evaluated in multiple clinical studies including two Phase 3
registrational clinical trials for metastatic pancreatic cancer and
r/r acute myeloid leukemia. Multiple Phase 1/2 clinical trials are
ongoing or planned in Biliary, r/r Burkitt, r/r Clear Cell Sarcoma,
r/r T-cell lymphoma, r/r MDS, and Colorectal cancer.
The Company plans continues to discover and advance its internal
cancer metabolism research programs and expects its Dual-SHMT
Inhibitor to enter Phase 1 in late 2022/early 2023. The Company's
investors include Rafael Holdings, Inc. (NYSE: RFL). For more
information, please visit www.rafaelpharma.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/rafael-holdings-expands-leadership-team-with-three-highly-experienced-global-biopharmaceutical-executives-to-build-a-fully-integrated-cancer-metabolism-therapeutics-company-301357000.html
SOURCE Rafael Holdings, Inc.